ClinicalTrials.Veeva

Menu

Procalcitonin as a Marker of Severity of Non-cystic Fibrosis Bronchiectasis in Children

A

Assiut University

Status

Not yet enrolling

Conditions

Non-cystic Fibrosis Bronchiectasis

Treatments

Diagnostic Test: procalcitonin

Study type

Observational

Funder types

Other

Identifiers

NCT06352944
AssiutMD

Details and patient eligibility

About

The aim of this study is to evaluate the role of procalcitonin in bronchoalveolar lavage as a biomarker for assessment of severity of non-CF bronchiectasis in children in correlation with other markers (functional and radiological severity )

Full description

• The severity of bronchiectasis will be assessed using forced expiratory volume in 1s (FEV1), and bronchiectasis severity scores which included bronchiectasis severity index (BSI) , FEV1, chronic colonization, extension of lobes and dyspnea which were performed to assess non-CF bronchiectasis patients.

BSI score

  • This score incorporates 9 variables. The total score is calculated by summing the scores for each variable and can range from 0 to 26 points. According to the overall score, patients are classified into three classes: patients with low BSI score (0---4 points), intermediate BSI score (5---8 points), high BSI score (≥9 points)
  • chest X ray and HRCT of the chest: to assess the radiological severity of bronchiectasis using the radiological findings will be measured by assessing the most recent chest X ray and HRCT of the chest performed in the last six months using Bhalla score(10)
  • Culture and sensitivity from bronchoalveolar lavage for isolation of pseudomonas aeruginosa and any other organism.
  • Sputum procalcitonin level was measured in BAL samples using bronchoscopy.
  • Bronchoscopy: would be undertaken when the children were in a stable clinical condition as part of their annual review

Enrollment

30 estimated patients

Sex

All

Ages

6 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Children of both sex
  2. Children aged from 6-17 years old.
  3. Documented diagnosis of non-CF bronchiectasis by confirmed bronchiectasis findings using high-resolution computed tomographic (HRCT) lung scanning, and clinical symptoms consistent with bronchiectasis with a negative sweat test

Exclusion criteria

  1. Age less than 6 years or more than 17 years.
  2. Children Diagnosed with cystic fibrosis bronchiectasis with confirmed positive sweat chloride test(6).
  3. If there was a history of a recent exacerbation during the previous month preceding the study.

Trial contacts and locations

0

Loading...

Central trial contact

maram M amir, lecturer

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems